author-photo

Brigitte Laguerre

University of Rennes

174

Papers

3559

Citations

Citation Trend

Filter By

Papers (174) Sort By

JournalConferenceOthers

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.

2021 Clinical Genitourinary Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Cabazitaxel multiple rechallenge in metastatic castration-resistant prostate cancer: A therapeutic option to increase overall survival?

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (26)
Safety and efficacy of nivolumab in older patients (pts) with renal cell carcinoma: Results of a sub-group analysis of the GETUG-AFU 26 NIVOREN multicenter phase II study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (14)
Prognosis impact of serous metastases (SMs) in clear cell renal cell carcinoma patients in the GETUG-AFU-26 NIVOREN phase II trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Adaptation of chemotherapy to the decline tumor markers in patients with poor prognosis nonseminomatous germ cell tumors:Real-world French experience.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Association of statins and nivolumab activity in patients with metastatic renal cell carcinoma (mRCC): Results from the phase II nivoren—GETUG AFU 26 trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
347 KEYNOTE-365 cohort C: pembrolizumab + enzalutamide in patients with abiraterone acetate–pretreated metastatic castration-resistant prostate cancer (mCRPC)—data after minimum of 22 months of follow-up

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号